Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies

• by Athanasios Tsianakas, Nina Magnolo, Afra Kempf, Frank Andersohn, Astrid Kirsch, Georgios Kokolakis, Dennis Niebel

• March 28, 2026

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

• by Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K. Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, Richard B. Warren

• May 17, 2026

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

• by Kathryn Wighton

• April 13, 2026

• 4 min

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

• by Andrea Surnit

• May 14, 2026

• 3 min